Pneumonia is an infection that causes inflammation and fluid accumulation in the lungs. During the course of the illness, microscopic, air-filled sacs in the lung, known as alveoli, often become inflamed and fill with fluid, resulting in coughing, chest pain, fever, and difficulty breathing.
While healthy individuals can develop pneumonia, young children and adults over the age of 65 tend to have more serious complications. People with conditions such as heart failure, diabetes, chronic obstructive pulmonary disease (COPD), or weakened immune systems tend to be more susceptible to developing pneumonia.
Approximately 1 million people with pneumonia are hospitalized in the United States each year, with an estimated 50,000 patients dying from the disease. Treatment for bacterial pneumonia includes the use of antibiotics, but antibiotics are ineffective in reaching their targeted bacteria within biofilms, and bacteria can develop resistance to the drugs.
Synspira is developing the proprietary modified polysaccharide molecule, SNSP115, for the treatment of pneumonia. SNSP115 targets and disrupts bacterial biofilms and potentiates the activity of antibiotics.